Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 30;16:17562864231181177. doi: 10.1177/17562864231181177

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Use of the oral steroid prednisolone before and after initiation of eculizumab (data for the effectiveness analysis set, n = 68). (a) Average daily dose of prednisolone in 4-week ranges, in which crosses represent means, horizontal lines represent medians, colored boxes represent first and third quartiles, whiskers represent minimum and maximum values, and circles represent outliers (defined as a value that is larger than 1.5 times the first to third quartile range). (b) Percentage of patients treated with prednisolone by average daily dose in 4-week ranges.